Skip to content
Clinical Trials – home

ALTIZIDE: A Comprehensive Guide for Patients with Heart Failure

2 / 3
trials open to patients / all trials
2+
Countries

In short

This article discusses the use of Altizide, a medication being studied in clinical trials for patients with heart failure with preserved ejection fraction (HFpEF). The research aims to evaluate the effectiveness of Altizide, in combination with other drugs, in improving outcomes for individuals with this specific type of heart condition.

At a glance

Study Drug
Altizide (in combination with spironolactone or eplerenone)
Condition Studied
Heart failure with preserved ejection fraction (HFpEF)
Primary Objective
Reduce heart failure hospitalizations and cardiovascular deaths
Key Eligibility Criteria
Age ≥50, LVEF ≥40%, elevated natriuretic peptides, regular loop diuretic use
Administration
Oral, max 50 mg daily, up to 120 days
Study Design
Registry-based Randomized Clinical Trial (RRCT)

What is ALTIZIDE?

ALTIZIDE is a medication that belongs to a class of drugs known as mineralocorticoid receptor antagonists (MRAs). It is often used in combination with another drug called spironolactone. ALTIZIDE is also known by its synonym, althiazide. This combination is being studied for its potential benefits in treating certain heart conditions.

Medical Conditions Treated by ALTIZIDE

The primary medical condition that ALTIZIDE is being investigated for is heart failure with preserved ejection fraction (HFpEF). This is a type of heart failure where the heart's ability to pump blood is preserved, but it has trouble filling with blood properly. It's important to understand that while ALTIZIDE is being studied for this condition, its use may not be limited to only this type of heart failure.

How ALTIZIDE Works

ALTIZIDE, in combination with spironolactone, works by blocking the effects of a hormone called aldosterone. This hormone can cause the body to retain salt and water, which can be problematic for people with heart failure. By blocking aldosterone, ALTIZIDE helps the body get rid of excess fluid, which can relieve some of the symptoms of heart failure.

Dosage and Administration

According to the clinical trial information, the maximum daily dose of ALTIZIDE (in combination with spironolactone) is 50 mg. The medication is taken orally, which means by mouth. The maximum treatment period mentioned in the trial is 120 days, but this may vary depending on individual patient needs and doctor's recommendations.

Who Can Take ALTIZIDE?

Based on the clinical trial criteria, ALTIZIDE may be suitable for patients who meet the following conditions:

  • Age 50 years or older
  • Diagnosed with stable heart failure
  • Left ventricular ejection fraction (LVEF) of 40% or higher
  • Elevated levels of certain heart failure markers in the blood (NT-proBNP or BNP)
  • Regular use of loop diuretics (another type of heart medication)
  • New York Heart Association (NYHA) Class II-IV heart failure symptoms

However, it's crucial to note that these are clinical trial criteria, and the actual eligibility for ALTIZIDE treatment should be determined by a healthcare professional.

Current Clinical Trial: SPIRRIT-HFpEF

ALTIZIDE is currently being studied in a clinical trial called SPIRRIT-HFpEF (Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction). This trial aims to assess whether adding spironolactone or eplerenone (another similar medication) to standard care can reduce hospitalizations due to heart failure or deaths from cardiovascular causes in patients with HFpEF.

Potential Side Effects and Precautions

While the clinical trial data doesn't provide specific information about side effects, it's important to be aware of potential risks associated with mineralocorticoid receptor antagonists like ALTIZIDE:

  • High potassium levels in the blood (hyperkalemia)
  • Low blood pressure
  • Kidney problems
  • Interactions with other medications

The trial excludes patients with certain conditions, which may indicate potential risks or contraindications:

  • Chronic liver disease
  • Very low kidney function (eGFR less than 30 ml/min/1.73m2)
  • Current dialysis treatment
  • High potassium levels (above 5.0 mmol/L)
  • Pregnancy or potential for pregnancy
  • Use of lithium medication

It's crucial to discuss any concerns or potential side effects with your healthcare provider before starting or during treatment with ALTIZIDE.

Questions people often ask

Conditions where Altizide is being studied

Each condition opens its own overview and trial list

Trials with Altizide

Recruiting trials first

See all 3 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.